Evidence for an involvement of the brain cholecystokinin B receptor in anxiety

Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1130-3. doi: 10.1073/pnas.88.4.1130.

Abstract

The effect of neuropeptide cholecystokinin (CCK) receptor agonists and antagonists was examined in the rat elevated X-maze model of anxiety. The selective CCK-B receptor antagonists CI-988 (PD 134308) and L-365,260 produced anxiolytic-like effects, whereas MK-329, a CCK-A receptor antagonist, was respectively less potent by factors of 313 and 200. The intracerebroventricular administration of the nonselective CCK receptor agonist caerulein or the selective CCK-B receptor agonist pentagastrin increased dose dependently the level of anxiety. CI-988 dose dependently antagonized the anxiogenic response to pentagastrin but not that induced by pentylenetetrazol. These results strongly suggest that activation of the brain CCK-B receptor induces anxiety and that selective antagonists of this receptor represent a separate class of anxiolytic agents.

MeSH terms

  • Animals
  • Anxiety*
  • Benzodiazepinones / administration & dosage
  • Benzodiazepinones / pharmacology*
  • Cerebral Ventricles / drug effects
  • Cerebral Ventricles / physiology*
  • Ceruletide / pharmacology
  • Chlordiazepoxide / administration & dosage
  • Chlordiazepoxide / pharmacology*
  • Cholecystokinin / antagonists & inhibitors*
  • Devazepide
  • Indoles / administration & dosage
  • Indoles / pharmacology*
  • Injections, Intraventricular
  • Male
  • Meglumine / administration & dosage
  • Meglumine / analogs & derivatives*
  • Meglumine / pharmacology
  • Pentagastrin / pharmacology
  • Phenylurea Compounds*
  • Rats
  • Rats, Inbred Strains
  • Receptors, Cholecystokinin / drug effects
  • Receptors, Cholecystokinin / physiology*

Substances

  • Benzodiazepinones
  • Indoles
  • Phenylurea Compounds
  • Receptors, Cholecystokinin
  • PD 134308
  • L 365260
  • Meglumine
  • Chlordiazepoxide
  • Ceruletide
  • Cholecystokinin
  • Pentagastrin
  • Devazepide